FDA lifts par­tial hold on Ar­cel­lx’s Gilead-part­nered blood can­cer cell ther­a­py as biotech aims for 2026 launch

Ar­cel­lx’s Gilead-part­nered mul­ti­ple myelo­ma cell ther­a­py is in the clear, as the FDA has re­moved the par­tial clin­i­cal hold it placed on the CAR-T can­di­date in June fol­low­ing a pa­tient death.

The Cal­i­for­nia drug­mak­er said Mon­day that the pa­tient who died was “man­aged in a man­ner that con­flict­ed with the tri­al pro­to­col.” The pa­tient was treat­ed with the ther­a­py even though they were in­el­i­gi­ble for it un­der the pro­to­col, Ar­cel­lx added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER